Observations placeholder
Daliresp
Identifier
018841
Type of Spiritual Experience
Background
A description of the experience
Roflumilast (trade names Daxas, Daliresp) is a drug that acts as a selective, long-acting inhibitor of the enzyme PDE-4 (Phosphodiesterase-4). It has anti-inflammatory effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as chronic obstructive pulmonary disease (COPD).
In June 2010, Daxas was approved in the EU for severe COPD associated with chronic bronchitis. In March 2011, Daliresp gained FDA approval in the US for reducing COPD exacerbations.
On Dec, 12, 2016 1,946 people reported to have side effects when taking Daliresp.
Among them, 15 people (0.77%) have Hallucination
Time on Daliresp when people have Hallucination :
< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Hallucination100.00%0.00%0.00%0.00%0.00%0.00%0.00%
On Dec, 1, 2015: 375 people reported to have side effects when taking Daliresp. Among them, 11 people (2.93%) have Death.
Time on Daliresp when people have Death :
< 1 month1 - 6 months6 - 12 months1 - 2 years2 - 5 years5 - 10 years10+ years Death80.00%20.00%0.00%0.00%0.00%0.00%0.00%